Cardiome Oxyprim Phase IV Trial Design Will Be Part Of Chronic Gout Trial Design Cmte. Meeting

The Phase IV proposal will act as a case study for FDA's Arthritis Advisory Committee's discussion June 2. The study will fulfill accelerated approval requirements for oxypurinol, which has a June 23 user fee date. The committee will also look at acute gout; Merck's Arcoxia will be discussed.